MarketCapExport financials
MorphoSys AG (MOR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
MorphoSys AG Cash Flow 2023-2011 | MOR
Brief overview of MorphoSys AG's cash movements
The comparison covers five available annual reports between 2017 and 2021.
Operating cash flow is negative at -€481.4 million, leaving internal funding capacity weak.
Positive operating cash flow appeared only 1 times out of five; a stable cash profile has not formed.
Overall picture
Taken together, MorphoSys AG's cash flow indicators point to increased dependence on reserves or outside financing.
Annual Cash Flow MorphoSys AG
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-296 M | -367 M | -481 M | 35.3 M | -81.1 M | -32.8 M | -38.4 M | -46.6 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Quarterly Cash Flow MorphoSys AG
| 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-296 M | -367 M | - | - | - | -481 M | - | - | - | 35.3 M | - | - | - | -81.1 M | - | - | - | -32.8 M | - | - | - | -38.4 M | - | - | - | -46.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Cash Flow Statement is one of the three key financial reports of the company MorphoSys AG, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Crinetics Pharmaceuticals
CRNX
|
$ 84.95 | 0.13 % | $ 7.99 B |  USA |
 |
ImmunoGen
IMGN
|
- | - | $ 7.92 B | USA |
 |
Galectin Therapeutics
GALT
|
$ 3.19 | -5.62 % | $ 204 M | USA |
 |
Genprex
GNPX
|
$ 1.81 | -8.59 % | $ 1.69 M | USA |
 |
GeoVax Labs
GOVX
|
$ 0.21 | -3.15 % | $ 201 K | USA |
 |
GlaxoSmithKline plc
GSK
|
$ 50.75 | -0.9 % | $ 206 B |  Britain |
 |
GT Biopharma
GTBP
|
$ 5.46 | -1.09 % | $ 30.1 M | USA |
 |
Vascular Biogenics Ltd.
VBLT
|
- | -8.77 % | $ 12.4 M |  Israel |
 |
Amarin Corporation plc
AMRN
|
$ 11.79 | 1.64 % | $ 4.89 B |  Irlanda |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | USA |
 |
Histogen
HSTO
|
- | 31.6 % | $ 2.12 M | USA |
 |
Halozyme Therapeutics
HALO
|
$ 125.63 | 0.88 % | $ 15.1 B | USA |
 |
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | USA |
 |
Hutchison China MediTech Limited
HCM
|
$ 14.36 | 0.56 % | $ 12.3 B |  China |
 |
AnaptysBio
ANAB
|
$ 48.73 | 1.31 % | $ 1.41 B | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
$ 36.13 | 0.28 % | $ 2.08 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.42 | 1.56 % | $ 307 M | USA |
 |
iBio
IBIO
|
$ 0.72 | -8.44 % | $ 74.9 M | USA |
 |
Axon Enterprise
AXON
|
$ 420.37 | 1.39 % | $ 32.8 B | USA |
 |
Immunome
IMNM
|
$ 17.99 | -1.48 % | $ 1.57 B | USA |
 |
Immuron Limited
IMRN
|
$ 0.95 | 0.44 % | $ 219 M |  Australia |
 |
InMed Pharmaceuticals
INM
|
$ 1.44 | 8.27 % | $ 6 M |  Canada |
 |
Inovio Pharmaceuticals
INO
|
$ 0.9 | 6.94 % | $ 42.2 M | USA |
 |
Insmed Incorporated
INSM
|
$ 93.39 | -1.76 % | $ 18.6 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 8.23 | 1.54 % | $ 554 B | Britain |
 |
Innoviva
INVA
|
$ 20.66 | -1.9 % | $ 1.39 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 42.93 | -2.23 % | $ 6.87 B | USA |
 |
Kaleido Biosciences
KLDO
|
- | -3.69 % | $ 12.4 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 224.03 | -1.43 % | $ 29.3 B | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.0 | -3.15 % | $ 428 M | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 3.46 | -3.08 % | $ 560 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 34.99 | 3.77 % | $ 147 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 9.84 | -8.29 % | $ 269 M | Israel |
 |
Alector
ALEC
|
$ 1.83 | -0.27 % | $ 188 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.71 | 3.06 % | $ 222 M |  France |
 |
Johnson & Johnson
JNJ
|
$ 263.81 | -1.46 % | $ 635 B | USA |
 |
argenx SE
ARGX
|
$ 873.71 | -0.23 % | $ 53.6 B |  Niderland |
 |
Arcutis Biotherapeutics
ARQT
|
$ 31.2 | -3.11 % | $ 3.97 B | USA |
 |
ObsEva SA
OBSV
|
- | -15.52 % | $ 10.5 M |  Schweiz |
 |
Cocrystal Pharma
COCP
|
$ 0.95 | 4.17 % | $ 10.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 243.37 | 0.16 % | $ 14.7 B |  Danmark |
 |
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 1.0 | 1.52 % | $ 230 M | USA |
 |
Landos Biopharma
LABP
|
- | 0.58 % | $ 144 M | USA |
 |
PhaseBio Pharmaceuticals
PHAS
|
- | 7.4 % | $ 6.29 M | USA |
 |
Legend Biotech Corporation
LEGN
|
$ 19.27 | 1.96 % | $ 7.1 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 303.53 | -1.39 % | $ 5.87 B | USA |
 |
Longeveron
LGVN
|
$ 1.6 | 0.63 % | $ 28.1 B | USA |
 |
Lipocine
LPCN
|
$ 1.44 | -1.37 % | $ 7.85 M | USA |